{
    "info": {
        "nct_id": "NCT05789082",
        "official_title": "A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation",
        "inclusion_criteria": "* Confirmation of Biomarker eligibility\n* Pre-treatment tumor tissue along with an associated pathology report is required for all participants enrolled on study. Representative tumor specimens must be in formalin-fixed, paraffin embedded (FFPE) blocks (preferred) or 15 unstained, freshly cut, serial slides. Although 15 slides are required, if only 10 slides are available, the participant may be eligible for the study following consultation with the Sponsor.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1\n* Histologically or cytologically documented locally advanced unresectable or metastatic NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy\n* No prior systemic treatment for advanced unresectable or metastatic NSCLC\n* Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Known concomitant second oncogenic driver with available targeted treatment\n* Squamous cell histology NSCLC\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Prior treatment with a KRAS G12C inhibitor\n* Known hypersensitivity to any of the components of divarasib or pembrolizumab; or known hypersensitivity to pemetrexed, carboplatin, or cisplatin (Cohort B only)\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis, active tuberculosis, significant cardiovascular disease within 3 months prior to initiation of study treatment\n* History of malignancy other than NSCLC within 5 years prior to initiation of study treatment, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate more >90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer\n* Uncontrolled tumor related pain, pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures, uncontrolled or symptomatic hypercalcemia",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Confirmation of Biomarker eligibility",
            "criterions": [
                {
                    "exact_snippets": "Confirmation of Biomarker eligibility",
                    "criterion": "biomarker eligibility",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically documented locally advanced unresectable or metastatic NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically documented",
                    "criterion": "NSCLC diagnosis method",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis method",
                            "expected_value": [
                                "histologically documented",
                                "cytologically documented"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced unresectable or metastatic NSCLC",
                    "criterion": "NSCLC stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "not eligible for curative surgery and/or definitive chemoradiotherapy",
                    "criterion": "eligibility for curative surgery and/or definitive chemoradiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "definition standard",
                            "expected_value": "Response Evaluation Criteria in Solid Tumors (RECIST) v1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No prior systemic treatment for advanced unresectable or metastatic NSCLC",
            "criterions": [
                {
                    "exact_snippets": "No prior systemic treatment for advanced unresectable or metastatic NSCLC",
                    "criterion": "prior systemic treatment for advanced unresectable or metastatic NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pre-treatment tumor tissue along with an associated pathology report is required for all participants enrolled on study. Representative tumor specimens must be in formalin-fixed, paraffin embedded (FFPE) blocks (preferred) or 15 unstained, freshly cut, serial slides. Although 15 slides are required, if only 10 slides are available, the participant may be eligible for the study following consultation with the Sponsor.",
            "criterions": [
                {
                    "exact_snippets": "Pre-treatment tumor tissue ... is required for all participants enrolled on study",
                    "criterion": "pre-treatment tumor tissue",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "associated pathology report is required",
                    "criterion": "pathology report",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Representative tumor specimens must be in formalin-fixed, paraffin embedded (FFPE) blocks (preferred) or 15 unstained, freshly cut, serial slides",
                    "criterion": "tumor specimen format",
                    "requirements": [
                        {
                            "requirement_type": "format",
                            "expected_value": [
                                "formalin-fixed, paraffin embedded (FFPE) block",
                                "15 unstained, freshly cut, serial slides"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "15 slides are required, if only 10 slides are available, the participant may be eligible for the study following consultation with the Sponsor",
                    "criterion": "number of unstained, freshly cut, serial slides",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 10,
                                        "unit": "slides"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Prior treatment with a KRAS G12C inhibitor",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with a KRAS G12C inhibitor",
                    "criterion": "KRAS G12C inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of malignancy other than NSCLC within 5 years prior to initiation of study treatment, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate more >90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer",
            "criterions": [
                {
                    "exact_snippets": "History of malignancy other than NSCLC within 5 years prior to initiation of study treatment",
                    "criterion": "history of malignancy other than NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate more >90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer",
                    "criterion": "history of specific low-risk malignancies",
                    "requirements": [
                        {
                            "requirement_type": "risk of metastasis or death",
                            "expected_value": "negligible"
                        },
                        {
                            "requirement_type": "5-year OS rate",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "malignancy type",
                            "expected_value": [
                                "adequately treated carcinoma in situ of the cervix",
                                "non-melanoma skin carcinoma",
                                "localized prostate cancer",
                                "ductal breast carcinoma in situ",
                                "Stage I uterine cancer"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis, active tuberculosis, significant cardiovascular disease within 3 months prior to initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "History of idiopathic pulmonary fibrosis",
                    "criterion": "idiopathic pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "organizing pneumonia (e.g., bronchiolitis obliterans)",
                    "criterion": "organizing pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bronchiolitis obliterans",
                    "criterion": "bronchiolitis obliterans",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "drug-induced pneumonitis",
                    "criterion": "drug-induced pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "idiopathic pneumonitis",
                    "criterion": "idiopathic pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of active pneumonitis",
                    "criterion": "active pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active tuberculosis",
                    "criterion": "active tuberculosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "significant cardiovascular disease within 3 months prior to initiation of study treatment",
                    "criterion": "significant cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Squamous cell histology NSCLC",
            "criterions": [
                {
                    "exact_snippets": "Squamous cell histology NSCLC",
                    "criterion": "non-small cell lung cancer (NSCLC) histology",
                    "requirements": [
                        {
                            "requirement_type": "histological subtype",
                            "expected_value": "squamous cell"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "progression status",
                            "expected_value": "actively progressing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known concomitant second oncogenic driver with available targeted treatment",
            "criterions": [
                {
                    "exact_snippets": "Known concomitant second oncogenic driver",
                    "criterion": "concomitant second oncogenic driver",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "knowledge_status",
                            "expected_value": "known"
                        }
                    ]
                },
                {
                    "exact_snippets": "with available targeted treatment",
                    "criterion": "targeted treatment for second oncogenic driver",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled tumor related pain, pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures, uncontrolled or symptomatic hypercalcemia",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled tumor related pain",
                    "criterion": "tumor related pain",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "pleural effusion ... requiring recurrent drainage procedures",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "requires recurrent drainage procedures",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pericardial effusion ... requiring recurrent drainage procedures",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "requires recurrent drainage procedures",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ascites requiring recurrent drainage procedures",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "requires recurrent drainage procedures",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled or symptomatic hypercalcemia",
                    "criterion": "hypercalcemia",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Known hypersensitivity to any of the components of divarasib or pembrolizumab; or known hypersensitivity to pemetrexed, carboplatin, or cisplatin (Cohort B only)",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to any of the components of divarasib",
                    "criterion": "hypersensitivity to divarasib components",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known hypersensitivity to any of the components of ... pembrolizumab",
                    "criterion": "hypersensitivity to pembrolizumab",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known hypersensitivity to pemetrexed",
                    "criterion": "hypersensitivity to pemetrexed",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known hypersensitivity to ... carboplatin",
                    "criterion": "hypersensitivity to carboplatin",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known hypersensitivity to ... cisplatin (Cohort B only)",
                    "criterion": "hypersensitivity to cisplatin",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cohort",
                            "expected_value": "B"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}